Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Paolo Paoletti(Heidelberg University), Salih Emri(Heidelberg University), James T. Symanowski(Heidelberg University), Claude Denham(Heidelberg University), U. Gatzemeier(Ontario Institute for Cancer Research), Michael Boyer(Chris O’Brien Lifehouse), Clet Niyikiza(Heidelberg University), Christian Manegold(Ontario Institute for Cancer Research), James J. Rusthoven(Heidelberg University), E. Kaukel(Heidelberg University), Pierre Ruffiè(Heidelberg University)
Cited by 3,063
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k